163 related articles for article (PubMed ID: 37506784)
1. Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response: Role of mTOR/G-CSF pathway.
Koni M; Lopatina T; Grange C; Sarcinella A; Cedrino M; Bruno S; Buffolo F; Femminò S; Camussi G; Brizzi MF
Pharmacol Res; 2023 Sep; 195():106871. PubMed ID: 37506784
[TBL] [Abstract][Full Text] [Related]
2. IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles.
Lopatina T; Koni M; Grange C; Cedrino M; Femminò S; Lombardo G; Favaro E; Brizzi MF
Pharmacol Res; 2022 May; 179():106206. PubMed ID: 35398240
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
Li C; Qiu S; Jin K; Zheng X; Zhou X; Jin D; Xu B; Jin X
Cancer Lett; 2021 Dec; 523():43-56. PubMed ID: 34601021
[TBL] [Abstract][Full Text] [Related]
4. The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche.
Blavier L; Nakata R; Neviani P; Sharma K; Shimada H; Benedicto A; Matei I; Lyden D; DeClerck YA
J Extracell Vesicles; 2023 May; 12(5):e12326. PubMed ID: 37194998
[TBL] [Abstract][Full Text] [Related]
5. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
[TBL] [Abstract][Full Text] [Related]
6. Xuanhusuo powder has an anti-breast cancer effect by inhibiting myeloid-derived suppressor cell differentiation in the spleen of mice through down-regulating granulocyte colony stimulating factor.
Mao Y; Liu X; He K; Lin C; He B; Gao J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 52(1):88-100. PubMed ID: 37283122
[TBL] [Abstract][Full Text] [Related]
7. Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition.
Wei H; Guo C; Zhu R; Zhang C; Han N; Liu R; Hua B; Li Y; Lin H; Yu J
J Ethnopharmacol; 2021 Dec; 281():113305. PubMed ID: 32890710
[TBL] [Abstract][Full Text] [Related]
8. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J; Yang J; Wang W; Guo D; Zhang C; Wang S; Lu X; Huang X; Wang P; Zhang G; Zhang J; Wang J; Cai Z
Cell Mol Immunol; 2022 Nov; 19(11):1290-1301. PubMed ID: 36220994
[TBL] [Abstract][Full Text] [Related]
9. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
[TBL] [Abstract][Full Text] [Related]
10. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
Dou X; Hua Y; Chen Z; Chao F; Li M
Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
[TBL] [Abstract][Full Text] [Related]
12. Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer-derived extracellular vesicles.
Barenholz-Cohen T; Merkher Y; Haj J; Shechter D; Kirchmeier D; Shaked Y; Weihs D
Int J Cancer; 2020 Nov; 147(10):2924-2933. PubMed ID: 32700789
[TBL] [Abstract][Full Text] [Related]
13. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
[TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles produced by bone marrow mesenchymal stem cells overexpressing programmed death-ligand 1 ameliorate dextran sodium sulfate-induced ulcerative colitis in rats by regulating Th17/Treg cell balance through PTEN/PI3K/AKT/mTOR axis.
He H; Chen Q; Fan H; Leng XY; Zhu F; Gao F; Zhou Q; Dong Y; Yang J
J Gastroenterol Hepatol; 2022 Dec; 37(12):2243-2254. PubMed ID: 36044618
[TBL] [Abstract][Full Text] [Related]
15. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
16. Blood flow diverts extracellular vesicles from endothelial degradative compartments to promote angiogenesis.
Mary B; Asokan N; Jerabkova-Roda K; Larnicol A; Busnelli I; Stemmelen T; Pichot A; Molitor A; Carapito R; Lefebvre O; Goetz JG; Hyenne V
EMBO Rep; 2023 Dec; 24(12):e57042. PubMed ID: 37971863
[TBL] [Abstract][Full Text] [Related]
17. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
19. Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.
Shukuya T; Ghai V; Amann JM; Okimoto T; Shilo K; Kim TK; Wang K; Carbone DP
J Thorac Oncol; 2020 Nov; 15(11):1773-1781. PubMed ID: 32565389
[TBL] [Abstract][Full Text] [Related]
20. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]